<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE270nnn/GSE270157/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Genomics</omics_type><species>Homo sapiens</species><gds_type>Genome binding/occupancy profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE270157</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Linker histone variant H1-10 promotes prostate cancer proliferation [ChIP-seq]</name><description>While the linker histone H1 is recognized for its role in stabilizing higher-order chromatin structures, the distinct functions of its variants remain underexplored. In this study, we uncover that the H1-10 is markedly overexpressed in prostate cancer and associates with a poor prognosis. H1-10 is mainly localized to the nucleolus, where it facilitates nucleolar assembly through liquid condensation. H1-10 amplifies ribosomal RNA (rRNA) transcription by directly associating with RNA polymerase I (Pol I), thereby enhancing Pol I binding affinity for ribosomal DNA (rDNA). This results in expanded production of rRNA and elevated global protein translation. By further investigation, we found that H1-10 boosts the protein translation of transcription factor E2F3, which in turn induces the transcription of cell growth genes by increasing the level of CTD serine 5 phosphorylated RNA polymerase II at gene promoters. Critically, through high-throughput virtual screening, we identified specific small molecules that inhibit H1-10 by targeting its DNA binding domain. On-target validations showed these molecules blocked H1-10-mediated Pol I rDNA occupancy, global protein translation and prostate tumor growth in vitro and in vivo. In summary, our study reveals the critical role of H1-10 in ribosome biogenesis and prostate cancer progression, and pioneers the pharmacological targeting of an H1 variant, highlighting the therapeutic promise of targeting histone variants.</description><dates><publication>2026/05/06</publication></dates><accession>GSE270157</accession><cross_references><GSM>GSM8335695</GSM><GSM>GSM8335684</GSM><GSM>GSM8335685</GSM><GSM>GSM8335696</GSM><GSM>GSM8335697</GSM><GSM>GSM8335686</GSM><GSM>GSM8335698</GSM><GSM>GSM8335687</GSM><GSM>GSM8335691</GSM><GSM>GSM8335692</GSM><GSM>GSM8335693</GSM><GSM>GSM8335683</GSM><GSM>GSM8335694</GSM><GSM>GSM8335703</GSM><GSM>GSM8335704</GSM><GSM>GSM8335699</GSM><GSM>GSM8335688</GSM><GSM>GSM8335700</GSM><GSM>GSM8335689</GSM><GSM>GSM8335701</GSM><GSM>GSM8335702</GSM><GSM>GSM8335690</GSM><GPL>24676</GPL><GPL>34284</GPL><GSE>270157</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>